You have 9 free searches left this month | for more free features.

City

Farmington (1)

New Haven (1)

New York (1)

Condition

Carcinoma, Non-Small-Cell Lung (1)

Esophageal Cancer (1)

Stomach Cancer (1)

Overall Status

Terminated (1)

Withdrawn (1)

Phase

phase 1 (1)

phase 3 (1)

Sponsor

Kadmon Corporation, LLC (1)

NYU Langone Health (1)

Collaborator

Intervention

kd019 (2)

erlotinib (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

kd019

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

NSCLC Trial in New Haven, Farmington (KD019, Erlotinib)

Terminated

Carcinoma, Non-Small-Cell Lung

KD019
Erlotinib

New Haven, Connecticut
+1 more

May 9, 2022

Esophageal Cancer, Stomach Cancer Trial in New York (KD019)

Withdrawn

Esophageal Cancer
Stomach Cancer

KD019

New York, New York

NYU Langone Medical Center

Jul 31, 2014